

1 Longitudinal prevalence and co-carriage of pathogens associated with 2 nursing home acquired pneumonia in three long-term care facilities

3
4 Ryann N. Whealy^{1,2}, Alexander Roberts^{1,2}, Tara N. Furstenau², Skylar Timm^{1,2}, Sara Maltinsky¹, Sydney Wells¹, Kylie
5 Drake¹, Kayla Ramirez¹, Candice Bolduc³, Ann Ross³, Talima Pearson¹, Viacheslav Y. Fofanov^{1,2}
6

7 ¹ Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, United States of America

8 ² School of Informatics, Computing, and Cyber Systems, Northern Arizona University, Flagstaff, Arizona, United States
9 of America.

10 ³ Mobile Dentistry of Arizona, Mesa, Arizona, United States of America
11

12 Corresponding authors:

13 Viacheslav Y. Fofanov

14 1295 Knoles Dr, Flagstaff, AZ 86011, USA

15 Viacheslav.Fofanov@nau.edu
16

17 Talima Pearson

18 1395 Knoles Dr, Flagstaff, AZ 86011, USA

19 Talima.Pearson@nau.edu
20

21 Word count: 3301
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Abstract

Nursing home acquired pneumonia (NHAP), and its subset – aspiration-associated pneumonia, is a leading cause of morbidity and mortality among residents in long-term care facilities (LTCFs). Understanding colonization dynamics of respiratory pathogens in LTCF residents is essential for effective infection control. This study examines the longitudinal trends in prevalence, persistence, bacterial load, and co-colonization patterns of five respiratory pathogens in three LTCFs in Phoenix, Arizona. Anterior nares and oral swabs were collected every other week and tested using qPCR for *Haemophilus influenzae*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, *Staphylococcus aureus*, and *Chlamydia pneumoniae*. Weekly average positivity rates were 17.75% for *H. influenzae* (0% - 39.39%), 9.95% for *P. aeruginosa* (0% - 37.74%), 31.89% for *S. pneumoniae* (1.79% - 41.67%), and for 28.00% for *S. aureus* (0% - 55.36%). *C. pneumoniae* was not detected. *H. influenzae* and *S. pneumoniae* predominantly colonized the oral cavity, while *P. aeruginosa* and *S. aureus* predominantly colonized the nasal cavity. *S. pneumoniae* and *S. aureus* colonizations were significantly more persistent than *H. influenzae* and *P. aeruginosa*, with persistence correlating with significantly higher bacterial loads. Co-colonization did occur in ~20% of positive samples, but appeared to be due to random chance. This study reveals distinct colonization patterns among respiratory pathogens in LTCF residents, highlighting differences in site-specific prevalence, persistence, and bacterial load. These findings underscore the importance of longitudinal monitoring to inform targeted infection control strategies in LTCFs.

Introduction

Nursing home acquired pneumonia (NHAP) is a leading cause of morbidity and mortality in long term care facilities (LTCFs), accounting for 40% of hospitalizations and up to 33% of deaths among residents [1]. It is estimated that 365 out of every 1000 LTCF residents are diagnosed with pneumonia annually [2], a rate 6-11 times higher than the incidence of pneumonia in elderly people living in the community [3,4]. Further, the medical care and treatment required for NHAP contribute to significant healthcare costs due to the potential for prolonged hospital stays, need for intensive care, and treatment-resistant etiologies. While pneumonia can often be treated by LTCF staff at an average cost of approximately \$3,700 [5], up to 30% of patients require hospitalization which increases average treatment cost to \$10,400 [6,7]. For patients who require hospitalization, mortality rates range from 13-45% [8,9]. These high costs and poor outcomes underscore the need for targeted, evidence-based infection prevention and stewardship strategies in nursing homes [10].

Micro-aspiration is the primary pathogenic mechanism of pneumonia in otherwise healthy individuals, while macro-aspiration (the cause of aspiration pneumonia) typically occurs only in those experiencing difficulty swallowing or changes in consciousness [11]. Older individuals are more likely to sustain an infection induced through aspirating large amounts of opportunistic pathogens due to decreased humoral and cell-mediated immunity, increased likelihood of underlying airway disorders, and altered levels of consciousness. Many bacterial etiological agents of pneumonia asymptotically colonize the oropharyngeal mucosa or other areas of the body. As such, sources of many pneumonia infections are endogenous and due to autoinfection [12]. Controlling pneumonia from endogenous sources requires management and control of these pathogens at individual and institutional levels to reduce the likelihood of acquisition, carriage, and infection.

Many pneumonia-causing bacteria colonize dental plaque biofilms [13–16], providing a potential source for micro- and macro-aspiration pneumonia [14,16]. Up to 80% correlation has been found between aerobic dental plaque colonization and the causative agent of aspiration associated-pneumonia [16]. Unsurprisingly, poor oral hygiene increases the risk of pneumonia [14,17–19], highlighting its potential as an intervention target. Further, elderly LTCF residents tend to have particularly poor oral health with high plaque scores [20], indicating that improving oral health among this population may be especially impactful. While promising, oral health interventions have shown mixed results in lowering NHAP incidence. In some studies, improved oral hygiene has been shown to decrease the incidence rate of pneumonia, potentially preventing as many as 10% of NHAP deaths [16,21–24]. Other studies have found no advantage in toothbrushing and chlorhexidine rinses over standard care in preventing NHAP [25]. In short, while the relationship

95 between colonization and infection is well established, much research still needs to be done to assess the potential for oral
96 hygiene interventions in reducing NHAP.

97
98 Due to the varied etiological agents involved in NHAP, characterization of longitudinal oral colonization and associated
99 transmission dynamics are critical for guiding future intervention studies. Furthering the understanding of the transmission
100 dynamics of the most common etiological agents responsible for NHAP (and, simultaneously, developing better assays to
101 detect them) will enable future intervention studies aimed at equipping LTCF clinicians with strategies for mitigation and
102 prevention. Towards this end, this study characterizes the colonization dynamics of common etiological agents of NHAP
103 in the oral and nasal cavity in LTCF residents.

104 **Methods**

105 **Sample and data collection**

106
107
108
109 Across three LTCFs in the Phoenix metropolitan area, 121 residents were enrolled to participate in this study after
110 providing written consent (IRB: 1766728). Participants provided their pneumonia vaccination status, as well as
111 demographic information (age, sex, and ethnicity). Swabs of the anterior nares and oral mucosa were collected every other
112 week from November 2021 to November 2023 (49 events total). Oral hygiene professionals supervised the self-sampling,
113 which has proven to be an effective and sensitive method of detecting pathogens at these body sites [26]. Collected swabs
114 were stored in 1mL of Liquid Amies at -20°C until processing.

115 **Sample processing, testing, and sequencing**

116 Multi-pathogen qPCR panel

117
118 Total DNA was extracted from nasal and oral swab samples using the Applied Biosystems MagMAX Viral and Pathogen
119 Nucleic Acid Isolation Kit with the KingFisher Flex system, according to the manufacturer's instructions. qPCR was
120 performed using a multi-pathogen panel (adapted from published assays) [27–31] designed to detect and quantify
121 *Haemophilus influenzae*, *Chlamydia pneumoniae*, *Pseudomonas aeruginosa*, *Streptococcus pneumoniae*, and
122 *Staphylococcus aureus* (Supplemental Table 1). We performed an in-silico PCR to evaluate the specificity of the primers
123 and probes across a comprehensive set of reference genomes for each pathogen. Some oligonucleotide sequences were
124 adjusted to maximize complementarity with a wider range of genomes. The assays were validated independently using
125 positive controls, and optimized to be run in duplex. There were interactions between oligos for *H. influenzae* and *S.*
126 *pneumoniae* as well as *S. aureus* and *P. aeruginosa*, but no other combinations produced cross-primer dimerization based
127 on in-silico PCR. Serial dilutions of quantitative genomic DNA were included in all runs to allow for relative DNA
128 quantification using standard curve analysis.

129
130
131 Each qPCR reaction was carried out in a 10 μ L volume containing 5 μ L of TaqMan Universal Master Mix, 2 μ L of
132 template DNA, final concentrations of 0.6 μ M for primers and 0.3 μ M for probes, and nuclease-free water. Cycling
133 conditions were as follows: 50°C for 2 minutes, 95°C for 15 minutes, then 45 cycles of 95°C for 15 seconds and 57°C for
134 1 minute. Amplifications were completed using an Applied Biosystems QuantStudio™ 7 Pro System, and results were
135 analyzed using the QuantStudio™ Design & Analysis Software (version 2.6.0).

136 Secondary validation using multi-pathogen amplicon sequencing

137
138 To confirm that the multiplex qPCR assays accurately identified the target species, we used a species-specific targeted
139 amplicon sequencing approach to detect additional genomic regions unique to each pathogen in a subset of qPCR positive
140 samples (Supplemental Table 2). The multiplex PCR was performed using the KAPA 2G Fast Multiplex PCR Master Mix
141 in 25 μ L reaction volumes, with 5ng of template DNA, 0.2 μ M concentration of each primer, and water to reach the final
142 volume. PCR thermocycling conditions consisted of an initial denaturation at 95°C for 3 minutes, followed by 35 cycles

of denaturation at 95°C for 15 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 1 minute and 30 seconds and a final extension at 72°C for 1 minute. PCR products were prepared for sequencing using our standard amplicon sequencing protocol [32] and were sequenced on the Illumina MiniSeq platform. Reads were aligned to reference genomes (Accessions in Supplemental Table 2) using BWA-MEM v0.7.17 [33].

Data analysis

All data cleaning and statistical analyses were conducted using R version 4.4.1. Statistical significance was set at a p-value of less than 0.05 for all tests. To minimize bias from sampling inconsistency, results are only included from participants who attended at least 1/3 of sampling events.

McNemar's test [34] was used to compare colonization rates between nasal and oral samples for each pathogen, accounting for the paired nature of the samples collected from the same participants. Matched odds ratios with 95% confidence intervals were calculated to quantify the magnitude of differences in colonization rates. To estimate the probabilities of transitioning between colonization states over time, we employed a Markov chain analysis with bootstrapping (1000 for each pathogen). The resulting transition matrices generated from bootstrapping were averaged to produce a final transition matrix representing the mean transition probabilities. Linear mixed models were fitted using the lme4 [35] and lmerTest [36] packages to quantify predictors of average relative DNA quantities. Full models included transient vs. persistent colonization, age, sex, pneumococcal vaccination, and recent estimated exposure as fixed effects as well as random intercepts for each participant to account for repeated measures. The results are reported in relative units (RQ), indicating fold changes in bacterial abundance relative to a standardized control. Co-colonization patterns were visualized using an upset plot created with the UpSetR [37] package, highlighting the intersections between different pathogens. To investigate potential temporal associations between colonization with different pathogens, we performed a correlation analysis incorporating current and lagged colonization statuses. However, no significant correlations were found, so this analysis was exploratory in nature.

Results

Participant description

The 121 participants ranged in age from 60 to 97 (median = 83, mean = 82.97) and were a majority female (76.03%). Race/ethnicity was not included in this analysis due to a significantly imbalanced distribution within the sample; approximately 96% of participants were non-Hispanic whites. The subset of participants who attended at least one-third of sampling events (n=85) closely matched the demographic distribution of the overall study population, with a mean age of 83 and approximately 3/4 being female. These individuals attended an average of 34 out of 49 sampling events, approximately 70% were vaccinated against streptococcal pneumonia, and were evenly distributed between the three LTCFs.

Colonization rates at nasal and oral sites

We observed wide ranges of colonization rates for the pathogens of interest and significant site-specificity towards the nasal or oral cavity. Of the approximately 6,000 samples collected from the 85 participants in LTCFs, 9.99% of samples were positive for *Haemophilus influenzae*, 5.78% were positive for *Pseudomonas aeruginosa*, 22.07% were positive for *Streptococcus pneumoniae*, and 18.01% were positive for *Staphylococcus aureus*. Notably, *Chlamydia pneumoniae* was not detected in any samples. Table 1 provides an overview of the colonization metrics for each pathogen. Across time points, notable variation was observed in both sample-level and individual-level positivity rates. The cumulative incidence values illustrate that a majority of participants were colonized by at least one of these pathogens during the study period.

Table 1: Colonization Metrics by Pathogen

Pathogen	Average weekly sample positivity (range)	Average weekly individual positivity (range)	Cumulative incidence
<i>H. influenzae</i>	9.81% (0–23.48)	17.75% (0–39.39)	81.18%
<i>P. aeruginosa</i>	5.56% (0–20)	9.95% (0–37.74)	83.53%
<i>S. pneumoniae</i>	21.70% (0.89–31.62)	31.89% (1.79–41.67)	78.82%
<i>S. aureus</i>	17.80% (0–36.13)	28.00% (0–55.36)	91.76%

189

190

191

192

193

194

195

196

197

Our findings indicate that these pathogens differentially colonize the oral and nasal cavities, with *H. influenzae* and *S. pneumoniae* predominating in the oral cavity, and *P. aeruginosa* and *S. aureus* more frequently detected in the nasal cavity (Table 2). These differences were statistically significant (McNemar's test, $p < 1 \times 10^{-6}$), suggesting that the observed distribution patterns are not due to random variation but reflect true biological differences in site-specific colonization. Matched odds ratios further quantify these disparities, demonstrating substantially reduced odds of nasal colonization for *H. influenzae* and *S. pneumoniae* relative to oral colonization, but notably increased odds of nasal colonization for *P. aeruginosa* and *S. aureus*.

Table 1: Colonization Metrics by Pathogen

Pathogen	Average weekly sample positivity (range)	Average weekly individual positivity (range)	Cumulative incidence
<i>H. influenzae</i>	9.81% (0–23.48)	17.75% (0–39.39)	81.18%
<i>P. aeruginosa</i>	5.56% (0–20)	9.95% (0–37.74)	83.53%
<i>S. pneumoniae</i>	21.70% (0.89–31.62)	31.89% (1.79–41.67)	78.82%
<i>S. aureus</i>	17.80% (0–36.13)	28.00% (0–55.36)	91.76%

198

199

200

201

202

203

204

205

206

Longitudinal colonization rates

There were statistically significant changes in participant positivity over time for some of the pathogens (Figure 1). *H. influenzae* colonization decreased over time in both sample types, while *P. aeruginosa*, *S. aureus*, and *S. pneumoniae* colonization decreased in nasal samples over time ($p < 0.01$). Oral colonization with *P. aeruginosa*, *S. pneumoniae*, and *S. aureus* did not significantly change over time. Colonization at the individual level changed significantly over time for *H. influenzae*, *P. aeruginosa*, and *S. aureus* ($p < 0.01$). These changes were not correlated with any measured variables and there were no changes in protocol during the study.




Figure 1. The proportion of individuals (from oral, nasal, or both sample types), nasal samples, and oral samples testing positive for each pathogen over the course of the study. Pathogens include *Haemophilus influenzae* (Hi, red), *Pseudomonas aeruginosa* (Pa, green), *Streptococcus pneumoniae* (Sp, blue), and *Staphylococcus aureus* (Sa, purple). Each dot represents the positivity rate for a collection event, with trends highlighting temporal dynamics in colonization prevalence across anatomical sites and pathogens.

207

208

Duration of colonization

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

The distribution of time participants spent colonized shows notable variability among pathogens (Figure 2). The proportion of time that participants spent colonized by *S. pneumoniae* and *S. aureus* exhibited a pronounced bimodal pattern with a peak near zero, indicating never or highly transient colonization, and another near one, reflecting persistent colonization. Interestingly, colonization by *P. aeruginosa* appears to be predominantly short-lived, with only rare cases of persistent colonization or carriage. Colonization with *H. influenzae* was similarly skewed, though less drastically. The observation that individuals tend to be colonized by *S. aureus* either a majority of the time or only transiently has previously been found [38,39]. Less is known about persistence of colonization with the other pathogens of interest in healthy individuals. To quantify this variability, participants were categorized as "never" (no colonization over the study), "transient" (colonization in <50% of sampling events), or "persistent" (colonization in \geq 50% of sampling events). For *H. influenzae*, 67.1% of participants experienced transient colonization, 18.8% were never colonized, and 14.1% were persistently colonized, indicating that *H. influenzae* colonization is mostly short-lived for otherwise healthy individuals. For *P. aeruginosa*, 82.4% were transient, 16.5% were never colonized, and 1.18% were persistently colonized, indicating that *P. aeruginosa* is not typically a long-term colonizer. In contrast, *S. pneumoniae* exhibited a more balanced pattern: 43.5% were transiently colonized, 21.2% were never colonized, and 35.3% were persistently colonized. For *S. aureus*, only 8.24% were never colonized, with 71.8% transiently colonized and 20% persistent colonization.




Figure 2. The proportion of events participants spent colonized by each pathogen (if colonized at least once); *Haemophilus influenzae* (Hi, red), *Pseudomonas aeruginosa* (Pa, green), *Streptococcus pneumoniae* (Sp, blue), and *Staphylococcus aureus* (Sa, purple). The distribution indicates variability in colonization duration across pathogens, with box plots embedded to show median and quartile ranges.

225

226

227

228

229

230

231

232

233

234

The average duration of continuous colonization at any of the two body sites was approximately 4 weeks for *H. influenzae*, 2.4 weeks for *P. aeruginosa*, 9.6 weeks for *S. pneumoniae*, and 8.8 weeks for *S. aureus* (of those that were colonized at least once during the study). Recurrent colonization (recolonization after pathogen was not detected and thus assumed to be cleared from an individual) was observed in 58.8% of participants for *H. influenzae*, 61.2% for *P. aeruginosa*, 57.6% for *S. pneumoniae*, and 72.9% for *S. aureus*. These colonization patterns are illustrated below (Figure 3). *S. pneumoniae* and *S. aureus* are often persistent colonizers, while *H. influenzae* and *P. aeruginosa* typically appear transiently. Interestingly, persistent colonization with *S. aureus* tends to be in the nasal cavity while persistent colonization with *S. pneumoniae* tends to occur in the oral cavity (Figure 3).




Figure 3. Colonization patterns of *Haemophilus influenzae* (Hi, red), *Pseudomonas aeruginosa* (Pa, green), *Streptococcus pneumoniae* (Sp, blue), and *Staphylococcus aureus* (Sa, purple) shown by A) Colonization at the individual level (from oral, nasal, or both sample types) across the study period where each row represents an individual participant grouped by their LTCF; B) Nasal colonization across the study period, showing varying persistence of pathogens over time in each sampled LTCF; C) Oral colonization across the study period, showing varying persistence of pathogens over time in each sampled LTCF; and D) Duration of continuous colonization for each pathogen at the individual level and at nasal and oral sites, highlighting variability.

Markov chains were used to provide a more nuanced understanding of colonization likelihood and stability over time. For *H. influenzae*, at any given time point, the probability of becoming colonized was 9.05%, with a 55.92% chance of maintaining colonization once established, indicating moderate persistence. *P. aeruginosa* showed a similar colonization probability of 9.05%, but only a 21.67% probability of remaining colonized, reflecting its low likelihood of sustained colonization. In contrast, *S. pneumoniae* had a 7.56% probability of colonizing but an 83.64% chance of remaining colonized, suggesting that *S. pneumoniae* is more persistent once established. For *S. aureus*, the colonization probability was 10.74%, with a 72.98% likelihood of continuing colonization once established.

To identify which factors most influenced bacterial load (and thus the amount of bacterial material available for macro-aspiration), relative DNA quantities during positive weeks were analyzed using linear mixed models for each pathogen. Participants who were never colonized by the pathogen of interest were excluded from this analysis to focus on the comparison between transient and persistent colonization. For all pathogens, a subjects' categorization of persistent or transient colonization was the most significant predictor of their bacterial load (except for *P. aeruginosa* which did not have a pronounced persistent category). For *H. influenzae*, *S. pneumoniae* and *S. aureus*, persistent colonization was associated with significantly higher bacterial DNA levels compared to transient colonization ($p < 0.001$).

Co-colonization

While colonization by a single pathogen was most common, co-positivity was observed nearly $\frac{1}{3}$ of the time that an individual was colonized (Figure 4). However, the co-colonization rates did not appear to be more frequent than what is expected by chance ($p > 0.4$, under assumption of independence of colonization events). Additionally, lagged colonization status analysis suggested that there is no evidence that colonization by one pathogen predicts colonization by another within the next month ($r < 0.2$).

258




Figure 4. Co-colonization observed throughout the study within individuals (i.e. considering both oral and nasal results). The bar chart at top shows the percent of instances where individuals who were positive for at least one pathogen were positive for a given combination of pathogens (filled black dots). Each row represents a pathogen, and the bar chart to the right shows the relative prevalence for each pathogen among individuals that tested positive for at least one pathogen.

259

260

261

Discussion

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

Findings from this study highlight several important colonization patterns among LTCF residents, all of which underscore the value of longitudinal data in revealing temporal variability and individual-level dynamics that would be impossible to capture with cross-sectional approaches. This study is strengthened by sample collection from multiple body sites, investigation of multiple pathogens, and the utilization of qPCR for pathogen detection, which has been shown to be an especially reliable method of detection in older populations [40]. Longitudinal data collection provides valuable information on how prevalence, persistence, bacterial load, and co-colonization patterns are affected temporally and on an individual and institutional basis. Additionally, this study provides valuable information about asymptomatic carriage in otherwise healthy individuals; the very few existing longitudinal NHAP research studies have been limited to hospitalized patients. These insights can guide the design of effective mitigation strategies for NHAP and associated etiological agents.

While average weekly prevalence rates of *H. influenzae* (average 17.75%), *P. aeruginosa* (9.95%), *S. pneumoniae* (31.89%), and *S. aureus* (28.00%) offer valuable cross-sectional snapshots, the high cumulative incidences over the study period (81.18%, 83.53%, 78.82%, and 91.76%, respectively), and the duration of individual carriage, reveal a much broader picture of participant exposure and colonization dynamics. Without tracking these pathogens over time, the episodic nature of colonization might obscure the extent of overall exposure. For instance, while weekly rates fluctuate significantly (e.g., *S. pneumoniae* ranging from 0.89% to 31.62% and *S. aureus* from 0% to 36.13%), the cumulative incidences highlight that almost all participants were colonized at least once over the course of a two-year period. These findings emphasize that point-prevalence measures alone underestimate the true burden of colonization, potentially leading to an incomplete understanding of pathogen carriage, transmission, and risks.

This study demonstrates distinct colonization patterns of these pathogens in the oral and nasal cavities. Interestingly, *Chlamydia pneumoniae* was absent from all samples, possibly due to its obligate intracellular life cycle and tendency to colonize lower respiratory tract tissue [41]. Over the two-year observation period, *H. influenzae* and *S. aureus* colonization decreased over time in their predominant niches. In contrast, nasal colonization rates of *P. aeruginosa* and *S. pneumoniae* increased as the study progressed. These temporal shifts occurred independently of participant demographics, sampling methods, or changes in study protocol, suggesting that underlying biological or ecological factors, rather than

288 measured external variables, influenced the observed trends. While sample collection from the nasal and oral cavity
289 allows characterization of site-specificity in these pathogens, it is likely that different strains may exhibit distinct site-
290 specificity. Future studies may benefit from increased genotypic resolution and expanding the number of body sites
291 sampled to further understand site-specificity and potential reservoirs for colonization and spread. Studies have shown
292 that increasing the number of body sites sampled, increasing the number of replicates tested, and using multiple detection
293 methods can minimize false negatives and increase prevalence estimates [26]. Consequently, it is likely that the estimates
294 presented here (using only qPCR for detection and only one replicate from two body sites) are conservative and under-
295 represent the true prevalence of colonization and co-colonization.

297 The categorization of participants into transient and persistent colonization groups provide insight into the different
298 strategies utilized by these pathogens. Markov chain simulations confirmed the dominance of transient colonization for *P.*
299 *aeruginosa*, and to a lesser degree *H. influenzae*, indicating that these pathogens frequently establish and then are cleared
300 without long-term colonization. Analysis of bacterial loads indicated that persistent colonization is associated with a
301 significantly higher bacterial burden for *H. influenzae*, *S. pneumoniae*, and *S. aureus*. This finding suggests that once these
302 pathogens establish persistent colonization, they are able to maintain higher bacterial densities, which could have
303 implications for transmission potential and clinical outcomes. This should also guide potential intervention strategies - for
304 example, attempting to disrupt persistent *S. aureus* colonization via oral healthcare interventions (when persistent
305 colonization appears to be in the nasal cavity) are likely to be ineffective.

307 Polymicrobial pneumonia represents up to 40% of cases with an identified cause [42]. The involvement of multiple
308 pathogens can significantly affect infection dynamics, often resulting in more complex clinical outcomes [42]. In our
309 study, co-colonization was a relatively frequent occurrence, observed approximately $\frac{1}{3}$ of the time that an individual was
310 colonized. However, these rates aligned with simulated expectations ($p > 0.4$), supporting the assumption of
311 independence. Consistent with this, no evidence was found that colonization by one pathogen predicts subsequent
312 colonization by another. Our findings suggest that effective preventions should focus on control of individual pathogen
313 colonization rather than a specialized approach to multiple pathogens.

315 This study highlights the complex dynamics of colonization in LTCFs, including variability in site-specific colonization,
316 the distinction between transient and persistent colonization, and the occurrence of co-colonization. Longitudinal data
317 collection was crucial, enabling a better understanding of colonization dynamics and persistence. These insights
318 emphasize the importance of targeted surveillance and intervention strategies that consider the temporal and specific
319 nature of colonization, particularly for high-risk pathogens like *S. aureus* and *P. aeruginosa*.

321 **Author Contributions**

322 This study was conceptualized by RNW, VYF, TP, and TNF. Data collection was carried out by CB, AR, TP, and TNF,
323 and formal analyses were performed by RNW and TNF. Writing was completed by RNW, TNF, TP, and AR. Wet lab
324 work and sample processing were performed by RNW, AR, ST, SM, SW, KD, and KR. All authors have reviewed the
325 manuscript.

326 **Acknowledgements**

327 This work was supported by the Centers for Disease Control and Prevention (contract 75D30121C11191 - TP) and the
328 National Institutes of Health (NIH) National Institute on Minority Health and Health Disparities (U54MD012388 - TP)
329 and National Institute of Allergy and Infectious Diseases (R15AI156771 - TP).

330
331
332
333
334
335

Appendix

Supplemental Table 1

Pathogen	Positive control	Oligo	Original sequence	Adjusted sequence	Notes
<i>H. influenzae</i> [27]	ATCC® 51907DQ™	Hi P6 F	CCA GCT GCT AAA GTA TTA GTA GAA	n/a	The primers amplified in 89% (85/95) of genomes (156bp amplicon).
		Hi P6 R	TTC ACC GTA AGA TAC TGT GCC	n/a	
		Hi P6 probe	CAG ATG CAG TTG AAG GTT ATT TAG	CRG ATG CAG TTR AAG GTT ATT TAR	The probe was not an exact match for any of the amplicons but worked for all with adjusted sequence
<i>C. pneumoniae</i> [28]	ATCC® VR-1360DQ™	CPTM1	CAT GGT GTC ATT CGC CAA GT	n/a	Primers amplified in 100% (12/12) of genomes (82bp) and probe was an exact match in each
		CPTM2	CGT GTC GTC CAG CCA TTT TA	n/a	
		CP probe	TCT ACG TTG CCT CTA AGA GAA AAC TTC AAG TTG GA	n/a	
<i>P. aeruginosa</i> [29]	ATCC® 47085DQ™	Pa23F	TCC AAG TTT AAG GTG GTA GGC TG	n/a	The primers amplified in 98% (522/532) of genomes (94bp amplicon). All of the amplicons contained an exact match to the probe. A slight change to the reverse primer improves this to 99% (527/532)
		Pa23R	ACC ACT TCG TCA TCT AAA AGA CGA C	ACC ACT TCG TCA TCT AAA AGA CRA C	
		Pa23P	AGG TAA ATC CGG GGT TTC AAG GCC	n/a	
<i>S. pneumoniae</i> [30]	Various isolates from Russakoff et al. confirmed using qPCR and WGS [26,43]	cpsA-348F	GCT GTT TTA GCA GAT AGT GAG ATC GA	GCT GTT TTA GCA GAT AGT GAK ATY GR	The primers initially amplified in only 54% (107/197) of genomes (a 67bp amplicon). After adjustment, this improved
		cpsA-415R	TCC CAG TCG GTG CTG TCA	TCC CAG TCG GTG CTR TCA	

336
337
338

		cpsA probe	AAT GTT ACG CAA CTG ACG AG	RAT GTT AYG CAA CTG AYG AG	to 89% (176/197). Initially, only 41% (81/197) of the amplicons had an exact match for the probe, but adding ambiguous bases increased this to 87% (172/197).
<i>S. aureus</i> [31]	ATCC® 700669DQ™	SaQuant_47F	AAC TAC TAG GGG AGC CTA ATR AT	n/a	n/a
		SaQuant_99_12 2R	GGT ACT AAC CAA ATC AGG TCA TAA	n/a	n/a
		SaQuant_74_98 FP	TGG CTG AGA TGA AYT GTT CAG ACC C	n/a	n/a

339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368

369
370
371
372
373

Supplemental Table 2

The genomic targets included established MLST targets [44–48] as well as additional pathogen-specific targets identified by selecting conserved regions from reference genome alignments within each species [49]. There were a total of 106 primer pairs: 11 for *C. pneumoniae*, 9 for *H. influenzae*, 36 for *P. aeruginosa*, 30 for *S. aureus*, and 20 for *S. pneumoniae*.

Species	Genome	Forward Primer Seq	Reverse Primer Seq
<i>C. pneumoniae</i>	NC_005043.1	AGCCGAATCCAGAACGT	ACCCGCGCTAGAAATGAC
<i>C. pneumoniae</i>	NC_005043.1	AGAGAGATCCATAGCCAGAA	ACCGAAGATGTATGGGTAAC
<i>C. pneumoniae</i>	NC_005043.1	GCTTACATCGCGTCAGT	CCTCGAAGACAGGGATCA
<i>C. pneumoniae</i>	NC_005043.1	AACTTCCCCCTGAGCAT	ACGTTCAAAAATTGCTCGTTT
<i>C. pneumoniae</i> [45]	NC_005043.1	GCTTTAGAATTARSARAWGC T	GATCCTCCGGTATCYGATCC
<i>C. pneumoniae</i> [45]	NC_005043.1	ATGCGCAAGATATCAGTGGG	AAAGCTCCRSTWGMTATMGGWA G
<i>C. pneumoniae</i> [45]	NC_005043.1	GCTTCTARAGTACTTTTAAAT G	TATTTTRGAAATYTTTKCSAGYCG
<i>C. pneumoniae</i> [45]	NC_005043.1	GGAGTCWCTACWAAAGAAG G	TCGTAYTGYACATCRAAAGG
<i>C. pneumoniae</i> [45]	NC_005043.1	CCTATGATGAATCTKATCAA TGG	TCTTCTTCRGCWAGMCCATCT
<i>C. pneumoniae</i> [45]	NC_005043.1	AGATCTTCTTCWGGRGGWA GAGA	TTCYTTCAKAACSTAGGTTTT
<i>C. pneumoniae</i> [45]	NC_005043.1	ATTA AAAAATGTGCTGCT	CCTTCAGGAACATTYAACCC
<i>H. influenzae</i>	NC_007146.2	CCGCTGTTCGCAGTTTG	CGTGCCAGTGCTGCAAT
<i>H. influenzae</i>	NC_007146.2	AAACTCAAGGTCGTGCAT	CGTGCGGTTTTGTACGT
<i>H. influenzae</i> [44]	NC_007146.2	GGTGCACCGGGTGCAGGTAA	CCTAAGATTTTATCTAACTC
<i>H. influenzae</i> [44]	NC_007146.2	ATGGCAGGTGCAAAAGAGAT	TTGTACAACAGGCTTTTGCG
<i>H. influenzae</i> [44]	NC_007146.2	CTTATCGTTGGTCTTGCCGT	TTGGCACTTCCACTTTTCC
<i>H. influenzae</i> [44]	NC_007146.2	ACCACTTTCGGCGTGGATGG	AAGATTTCCAGGTGCCAGA
<i>H. influenzae</i> [44]	NC_007146.2	TCATTGTATGATATTGCCCC	ACTTCTGTACCTGCATTTTG
<i>H. influenzae</i> [44]	NC_007146.2	GGTGAAAAAATCAATCGTAC	ATTGAAAGACCAATAGCTGA
<i>H. influenzae</i> [44]	NC_007146.2	ATGGCAACTCAAGAAGAAA A	TTACCAAACATCACGCCTAT
<i>P. aeruginosa</i>	NC_002516.2	CGCCAGCTGTTTCAGTT	ACTCGCCTATGCGATCT
<i>P. aeruginosa</i>	NC_002516.2	AGCGCAGGAGGTTTTCC	CGCCGTGAGGAAATCAG
<i>P. aeruginosa</i>	NC_002516.2	GCCACGTGCGTAATATGC	TCCACATCCGCTGCATT

<i>P. aeruginosa</i>	NC_002516.2	ACCAGGGTACGCTCGTT	ACGTGATCCGCGGTATC
<i>P. aeruginosa</i>	NC_002516.2	GTCAGCGTGACCCGMAT	CGTTGCAGCAACTGCAT
<i>P. aeruginosa</i>	NC_002516.2	TGTAGCCGGCTAATTTCC	CGTCAGCCTTGCGATAG
<i>P. aeruginosa</i>	NC_002516.2	TAGGACTCCGCGGTCAT	GAAAGCCCAGCAATTGC
<i>P. aeruginosa</i>	NC_002516.2	TTGCGCCGACAGACTAC	CTCGGCGTGAAGGAAGA
<i>P. aeruginosa</i>	NC_002516.2	TCCAGCTCGACCACSGT	ATCGTCCTCGCGGTGAT
<i>P. aeruginosa</i>	NC_002516.2	ACGCTGCCTCCATAGTG	TAGTGGTGCCGCTTGAG
<i>P. aeruginosa</i>	NC_002516.2	CAGACGCGAGATTTCTGT	AATCGCGATGGGCGATA
<i>P. aeruginosa</i>	NC_002516.2	ATGGCGCTCTCCAAGGA	TGCAGCGGTTTCAACAG
<i>P. aeruginosa</i>	NC_002516.2	ACCAGGGAAAGCTGGAA	ATGCCCTGGCCGTSPTY
<i>P. aeruginosa</i>	NC_002516.2	ACGAAGCTGCGCAGAAC	TCGTGCGACAGTTCGAA
<i>P. aeruginosa</i>	NC_002516.2	GTTCCCGTTCCGGCTGAA	CGCCGATGGTGTAGTTG
<i>P. aeruginosa</i>	NC_002516.2	TCCARCTGGAAACCGCAAT	TGGCGGACTTCCGTTTC
<i>P. aeruginosa</i>	NC_002516.2	ACCATCCCCTTCAAGGA	TGGCCAAAGGGATCAGA
<i>P. aeruginosa</i>	NC_002516.2	AGCTTGGGATCGACGTA	AATGACGGCGTGAATGC
<i>P. aeruginosa</i>	NC_002516.2	TCCACTTTCGCGAACAG	TTCCGCCGTCGTAAGCA
<i>P. aeruginosa</i>	NC_002516.2	ATGACCCCGCACGATTC	AGCCGTCATGTCCGATT
<i>P. aeruginosa</i>	NC_002516.2	CAACGCGGTGACCCGTG	TGGACTTGGGGAACTGC
<i>P. aeruginosa</i>	NC_002516.2	CGGCACCGAACTGATCA	CTCGCCCTGGATCAGTA
<i>P. aeruginosa</i>	NC_002516.2	ACACCTCCAGGGTGTACTC	TAGGGATGGGCGTTTCG
<i>P. aeruginosa</i>	NC_002516.2	CACCCTGTCGACGGTAT	ARTCCTCCAGTCCGGTC
<i>P. aeruginosa</i>	NC_002516.2	GAGGGTGCCGTCGAAGT	GTGCTCGGCAAGTTCCA
<i>P. aeruginosa</i>	NC_002516.2	CTGGTCAAGCGGGTGAT	AACTCGTCCACCAGGAT
<i>P. aeruginosa</i>	NC_002516.2	TGATCGATCCGCAAGCG	GGTCGAAATCGGGTGAGA
<i>P. aeruginosa</i>	NC_002516.2	CAGGCTGACGCAAGCAT	TGCACCTGGGCATAGAC
<i>P. aeruginosa</i>	NC_002516.2	ACGATGAACACGGTGGC	AACTGCCCTGTGAAACG
<i>P. aeruginosa</i> [46]	NC_002516.2	GCCACACCTACATCGTCTAT	AGGTTGCCGAGGTTGTCCAC
<i>P. aeruginosa</i> [46]	NC_002516.2	ATGTCACCGTGCCGTTCAAG	TGAAGGCAGTCGGTTCCTTG
<i>P. aeruginosa</i> [46]	NC_002516.2	AGGTCGGTTCCTCCAAGGTC	GACGTTGTGGTGC GACTTGA
<i>P. aeruginosa</i> [46]	NC_002516.2	AGAAGACCGAGTTCGACCAT	GGTGCCATAGAGGAAGTCAT

<i>P. aeruginosa</i> [46]	NC_002516.2	ACGGCGAGAACGAGGACTA C	TGGCGGTTCGGTGAAGGTGAA
<i>P. aeruginosa</i> [46]	NC_002516.2	GGTGACGACGGCAAGCTGTA	GTATCGCCTTCGGCACAGGA
<i>P. aeruginosa</i> [46]	NC_002516.2	TTCAACTTCGGCGACTTCCA	GGTGTCCATGTTGCCGTTCC
<i>S. pneumoniae</i>	NZ_CP020549.1	AATGTTGCTGGACGTGC	TAGTGTTTGTTRTTGTGAAATAGCA
<i>S. pneumoniae</i>	NZ_CP020549.1	GTCAAGACCACCAGTAACG	TCGTGAGCATGTAGACT
<i>S. pneumoniae</i>	NZ_CP020549.1	GCTACAATCGGTAGCACAA	TGTCGAGACTACTCGTCAT
<i>S. pneumoniae</i>	NZ_CP020549.1	AACTCGGGATGACTCTCT	CCCAACGTCTGGGAGTT
<i>S. pneumoniae</i>	NZ_CP020549.1	AGAATGTCAACTACCTCTCT CT	AACCAAGCGAAGCTAAGG
<i>S. pneumoniae</i>	NZ_CP020549.1	TCTAGCCCTGCTTAAACTAG T	CAAGCGTGTCCGTTACC
<i>S. pneumoniae</i>	NZ_CP020549.1	TCGTAACAACCTGCTAACACT	GCCCCGTAACYCTACAAC
<i>S. pneumoniae</i>	NZ_CP020549.1	AACAAGACATACTMCCCTAC AC	CTAAAAAGTTACTAAAAATAAAA AN
<i>S. pneumoniae</i>	NZ_CP020549.1	AGCTAACCGTGCATTCG	AACCCRGGCTAAAGTTAGTTAG
<i>S. pneumoniae</i>	NZ_CP020549.1	CCGTTACACGCGATGA	AGCCCAAGTGTAAGCA
<i>S. pneumoniae</i>	NZ_CP020549.1	ATTGTTTGGGCACCTCTT	GGGGATATAGAAAACAAGACCC
<i>S. pneumoniae</i>	NZ_CP020549.1	TGAGCGTGTCAAATTCCA	AGAGTACAGCACCCTGT
<i>S. pneumoniae</i>	NZ_CP020549.1	CAGCGCTAGCTCACAGA	CAACTGATCCAGCCCAAT
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	GCCTTTGAGGCGACAGC	TGCAGTTCARAAACATWTTCTAA
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	ATGGACAAACCAGCNAGYTT	GCTTGAGGTCCCATRCTNCC
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	GGCATTGGAATGGGATCACC	TCTCCCGCAGCTGACAC
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	GCCAACTCAGGTCATCCAGG	TGCAACCGTAGCATTGTAAC
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	TTATTCCTCCTGATTCTGTC	GTGATTGGCCAGAAGCGGAA
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	TTATTAGAAGAGCGCATCCT	AGATCTGCCTCCTTAAATAC
<i>S. pneumoniae</i> [47]	NZ_CP020549.1	TGCYCAAGTTCCTTATGTGG	CACTGGGTRAAACCWGGCAT
<i>S. aureus</i>	NC_007795.1	GTCCAGGTAGCATGATT	TGTCATAACCAGTTAGGAATCACA
<i>S. aureus</i>	NC_007795.1	AATTAAGTAAGCTCCAATGC GTT	TAGTTCGCTCTCCCCTTA
<i>S. aureus</i>	NC_007795.1	TCCAATATCCTGGCGTGA	TTCACAACCATTACCAAG
<i>S. aureus</i>	NC_007795.1	TAACGATGCGACAGGTACAG	ATGATGATGCTATGCGT
<i>S. aureus</i>	NC_007795.1	AGGTCTCACGACATCATT	CATAATACCTGCGCCATCA

<i>S. aureus</i>	NC_007795.1	CGGACAAGAACATGTCAC	TGAATTAGTCCCCTGCG
<i>S. aureus</i>	NC_007795.1	GATGCAGAATACTCAAATGT	CGCCGTTATCATAGAAGCTATAC
<i>S. aureus</i>	NC_007795.1	GGAGTTATCATGCCAACAGT TATA	GCGCTTCTTCTGCACCCAT
<i>S. aureus</i>	NC_007795.1	CTCACCTCTACTTCTTATGGA	CACATCCATGATTTTCGTGCTCT
<i>S. aureus</i>	NC_007795.1	TACAAGCTAGGTTCGAAAGAA ATAC	CTTGTAACAACCTTTAACTTAGCTT
<i>S. aureus</i>	NC_007795.1	TCACATCATTTAAATCGCCA C	GCGCAGGTAGATTAATGC
<i>S. aureus</i>	NC_007795.1	GCAACTTCCATCGAACCGAC AGTC	TAATAGAGGAGTGTAGCACT
<i>S. aureus</i>	NC_007795.1	GACCTACAGCGATTCTT	TACACAAGCTCTGAATCG
<i>S. aureus</i>	NC_007795.1	GTGTCGAATTTTTATGCAT	AAACTTATAACTACGGCATTCTTT G
<i>S. aureus</i>	NC_007795.1	ATTAGGCGTTGTCGCA	AACAGGTATCTTATTGCATAATAT
<i>S. aureus</i>	NC_007795.1	ATCCTGACACTTACATTCCAT	CCACTGCCACCTGTTCG
<i>S. aureus</i>	NC_007795.1	CACCTACACGAATCATTGAC AA	AGCAGGTGGTGCACCTTATC
<i>S. aureus</i>	NC_007795.1	ACATTGAGCCATACTTCCA	TTAGAAGGTCCTCGAGA
<i>S. aureus</i>	NC_007795.1	TCCTGTCCAAGTGTAATGAT AA	CGTTACAGCTACAATCGCTAC
<i>S. aureus</i>	NC_007795.1	AAGTTATGGACTTAGACATT CTA	TGGACAAGGTTGGTAATAGCGA
<i>S. aureus</i>	NC_007795.1	ACCATCTTCTATCGTTTTATC A	GCTGCAAGTATATTACATGA
<i>S. aureus</i>	NC_007795.1	TCAGCTGTGTTTCGTTGT	AATTAGGACAATACGTATATGAA CA
<i>S. aureus</i>	NC_007795.1	TTTTCAAGGCTGTTTTTTATG CG	CGATTGTATGTGTGCCAATAATA
<i>S. aureus</i> [48]	NC_007795.1	TTGATTCACCAGCGCGTATT GTC	AGGTATCTGCTTCAATCAGCG
<i>S. aureus</i> [48]	NC_007795.1	ATCGGAAATCCTATTTTACA TTC	GGTGTGTATTAATAACGATATC
<i>S. aureus</i> [48]	NC_007795.1	CTAGGAACTGCAATCTTAAT CC	TGGTAAAATCGCATGTCCAATTC
<i>S. aureus</i> [48]	NC_007795.1	ATCGTTTTATCGGGACCATC	TCATTAACTACAACGTAATCGTA
<i>S. aureus</i> [48]	NC_007795.1	GTTAAAATCGTATTACCTGA AGG	GACCCTTTTGTGAAAAGCTTAA

<i>S. aureus</i> [48]	NC_007795.1	TCGTTTCATTCTGAACGTCGTG AA	TTTGCACCTTCTAACAATTGTAC
<i>S. aureus</i> [48]	NC_007795.1	CAGCATAACAGGACACCTATT GGC	CGTTGAGGAATCGATACTGGAAC

374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416

Citations

1. Griffith MF, Levy CR, Parikh TJ, Stevens-Lapsley JE, Eber LB, Palat S-IT, et al. Nursing Home Residents Face Severe Functional Limitation or Death After Hospitalization for Pneumonia. *J Am Med Dir Assoc.* 2020;21: 1879–1884.
2. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. *Am J Med.* 1998;105: 319–330.
3. Marrie TJ. Pneumonia in the long-term-care facility. *Infect Control Hosp Epidemiol.* 2002;23: 159–164.
4. Henig O, Kaye KS. Bacterial Pneumonia in Older Adults. *Infect Dis Clin North Am.* 2017;31: 689–713.
5. Kruse RL, Mehr DR, Boles KE, Lave JR, Binder EF, Madsen R, et al. Does hospitalization impact survival after lower respiratory infection in nursing home residents? *Med Care.* 2004;42: 860–870.
6. Loeb M, Carusone SC, Goeree R, Walter SD, Brazil K, Krueger P, et al. Effect of a clinical pathway to reduce hospitalizations in nursing home residents with pneumonia: a randomized controlled trial. *JAMA.* 2006;295: 2503–2510.
7. Dempsey CL. Nursing home-acquired pneumonia: outcomes from a clinical process improvement program. *Pharmacotherapy.* 1995;15: 33S–38S.
8. Gloth FM 3rd, Burton JR. Autopsies and death certificates in the chronic care setting. *J Am Geriatr Soc.* 1990;38: 151–155.
9. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. *Eur Respir J.* 2001;18: 362–368.
10. Crnich CJ, Jump R, Trautner B, Sloane PD, Mody L. Optimizing Antibiotic Stewardship in Nursing Homes: A Narrative Review and Recommendations for Improvement. *Drugs & Aging.* 2015;32: 699–716.
11. Overview of Pneumonia. *Goldman’s Cecil Medicine.* W.B. Saunders; 2012. pp. 587–596.
12. Pathophysiology of Pneumonia. *Clinics in Chest Medicine.* 2005;26: 39–46.
13. Scannapieco FA, Stewart EM, Mylotte JM. Colonization of dental plaque by respiratory pathogens in medical intensive care patients. *Crit Care Med.* 1992;20: 740–745.
14. Russell SL, Boylan RJ, Kaslick RS, Scannapieco FA, Katz RV. Respiratory pathogen colonization of the dental plaque of institutionalized elders. *Spec Care Dentist.* 1999;19: 128–134.
15. Didilescu AC, Skaug N, Marica C, Didilescu C. Respiratory pathogens in dental plaque of hospitalized patients with chronic lung diseases. *Clin Oral Investig.* 2005;9: 141–147.
16. El-Solh AA, Pietrantonio C, Bhat A, Okada M, Zambon J, Aquilina A, et al. Colonization of dental plaques: a reservoir of respiratory pathogens for hospital-acquired pneumonia in institutionalized elders. *Chest.* 2004;126: 1575–1582.
17. Hong C, Aung MM, Kanagasabai K, Lim CA, Liang S, Tan KS. The association between oral health status and respiratory pathogen colonization with pneumonia risk in institutionalized adults. *Int J Dent Hyg.* 2018;16: e96–e102.
18. Quagliarello V, Ginter S, Han L, Van Ness P, Allore H, Tinetti M. Modifiable risk factors for nursing home-acquired pneumonia. *Clin Infect Dis.* 2005;40: 1–6.
19. Abe S, Ishihara K, Adachi M, Okuda K. Oral hygiene evaluation for effective oral care in preventing pneumonia in dentate elderly. *Arch Gerontol Geriatr.* 2006;43: 53–64.

- 456 20. Chalmers J, Pearson A. Oral hygiene care for residents with dementia: a literature review. *J Adv Nurs*. 2005;52: 410–
457 419.
- 458 21. Grap MJ, Munro CL, Hamilton VA, Elswick RK Jr, Sessler CN, Ward KR. Early, single chlorhexidine application
459 reduces ventilator-associated pneumonia in trauma patients. *Heart Lung*. 2011;40: e115–22.
- 460 22. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. Oral hygiene care for critically ill patients to prevent
461 ventilator-associated pneumonia. *Cochrane Database Syst Rev*. 2016;10: CD008367.
- 462 23. Sjögren P, Nilsson E, Forsell M, Johansson O, Hoogstraate J. A systematic review of the preventive effect of oral
463 hygiene on pneumonia and respiratory tract infection in elderly people in hospitals and nursing homes: effect
464 estimates and methodological quality of randomized controlled trials. *J Am Geriatr Soc*. 2008;56: 2124–2130.
- 465 24. Bassim CW, Gibson G, Ward T, Paphides BM, Denucci DJ. Modification of the risk of mortality from pneumonia
466 with oral hygiene care. *J Am Geriatr Soc*. 2008;56: 1601–1607.
- 467 25. Juthani-Mehta M, Van Ness PH, McGloin J, Argraves S, Chen S, Charpentier P, et al. A cluster-randomized
468 controlled trial of a multicomponent intervention protocol for pneumonia prevention among nursing home elders.
469 *Clin Infect Dis*. 2015;60: 849–857.
- 470 26. Russakoff B, Wood C, Lininger MR, Barger SD, Trotter RT, Maltinsky S, et al. A Quantitative Assessment of
471 *Staphylococcus aureus* Community Carriage in Yuma, Arizona. *J Infect Dis*. 2023;227: 1031–1041.
- 472 27. Abdeldaim GMK, Strålin K, Korsgaard J, Blomberg J, Welinder-Olsson C, Herrmann B. Multiplex quantitative PCR
473 for detection of lower respiratory tract infection and meningitis caused by *Streptococcus pneumoniae*, *Haemophilus*
474 *influenzae* and *Neisseria meningitidis*. *BMC Microbiol*. 2010;10: 310.
- 475 28. Welti M, Jatton K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR
476 assay to detect *Chlamydia pneumoniae*, *Legionella pneumophila* and *Mycoplasma pneumoniae* in respiratory tract
477 secretions. *Diagn Microbiol Infect Dis*. 2003;45: 85–95.
- 478 29. Improved early diagnosis of *Pseudomonas aeruginosa* by real-time PCR to prevent chronic colonisation in a
479 paediatric cystic fibrosis population. *J Cyst Fibros*. 2011;10: 21–24.
- 480 30. Park HK, Lee HJ, Kim W. Real-time PCR assays for the detection and quantification of *Streptococcus pneumoniae*.
481 *FEMS Microbiol Lett*. 2010;310: 48–53.
- 482 31. Wood C, Sahl J, Maltinsky S, Coyne B, Russakoff B, Yagüe DP, et al. SaQuant: a real-time PCR assay for
483 quantitative assessment of *Staphylococcus aureus*. *BMC Microbiol*. 2021;21: 1–7.
- 484 32. Williamson CHD, Vazquez AJ, Nunnally AE, Kyger K, Fofanov VY, Furstenau TN, et al. ColiSeq: a multiplex
485 amplicon assay that provides strain level resolution of directly from clinical specimens. *Microbiol Spectr*. 2024;12:
486 e0413923.
- 487 33. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013. Available:
488 <http://arxiv.org/abs/1303.3997>
- 489 34. Website. Available: R Core Team (2024). *_R: A Language and Environment for Statistical Computing_*. R
490 Foundation for Statistical Computing, Vienna, Austria. <<https://www.R-project.org/>>.
- 491 35. Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models Using lme4. *J Stat Softw*. 2015;67.
492 doi:10.18637/jss.v067.i01
- 493 36. Kuznetsova A, Brockhoff PB, Christensen RHB. LmerTest package: Tests in linear mixed effects models. *J Stat*
494 *Softw*. 2017;82. doi:10.18637/jss.v082.i13
- 495 37. Gehlenborg N. A More Scalable Alternative to Venn and Euler Diagrams for Visualizing Intersecting Sets [R

- 496 package UpSetR version 1.4.0]. 2019 [cited 1 Dec 2024]. Available: <https://CRAN.R-project.org/package=UpSetR>
- 497 38. Nouwen JL, Fieren MWJA, Snijders S, Verbrugh HA, van Belkum A. Persistent (not intermittent) nasal carriage of
498 *Staphylococcus aureus* is the determinant of CPD-related infections. *Kidney Int.* 2005;67: 1084–1092.
- 499 39. de Vogel CP Boelens HA Verveer J Nouwen JL Verbrugh HA Wertheim HF van BAVN. Reclassification of
500 *Staphylococcus aureus* nasal carriage types. *J Infect Dis.* 2009. doi:10.1086/599119
- 501 40. Sutcliffe CG, Grant LR, Cloessner E, Klugman KP, Vidal JE, Reid R, et al. Association of Laboratory Methods,
502 Colonization Density, and Age With Detection of *Streptococcus pneumoniae* in the Nasopharynx. *Am J Epidemiol.*
503 2019;188: 2110–2119.
- 504 41. Porritt RA, Crother TR. *Chlamydia pneumoniae* Infection and Inflammatory Diseases. *OT.* 2016;7.
505 doi:10.1615/ForumImmunDisTher.2017020161
- 506 42. Cillóniz C, Civljak R, Nicolini A, Torres A. Polymicrobial community-acquired pneumonia: An emerging entity.
507 *Respirology.* 2016;21: 65–75.
- 508 43. Pearson T, Hepp C, Trotter RT, Mbegbu M, Russakoff B, Panisello YD, et al. Genome Sequences of Community
509 Carriage Strains of *Staphylococcus aureus* from Yuma, Arizona. *Microbiology resource announcements.* 2021;10.
510 doi:10.1128/MRA.00449-21
- 511 44. Meats E, Feil EJ, Stringer S, Cody AJ, Goldstein R, Kroll JS, et al. Characterization of encapsulated and
512 noncapsulated *Haemophilus influenzae* and determination of phylogenetic relationships by multilocus sequence
513 typing. *J Clin Microbiol.* 2003;41: 1623–1636.
- 514 45. Pannekoek Y, Morelli G, Kusecek B, Morré SA, Ossewaarde JM, Langerak AA, et al. Multi locus sequence typing
515 of Chlamydiales: clonal groupings within the obligate intracellular bacteria *Chlamydia trachomatis*. *BMC Microbiol.*
516 2008;8: 42.
- 517 46. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the
518 opportunistic pathogen *Pseudomonas aeruginosa*. *J Clin Microbiol.* 2004;42: 5644–5649.
- 519 47. Enright MC, Spratt BG. A multilocus sequence typing scheme for *Streptococcus pneumoniae*: identification of
520 clones associated with serious invasive disease. *Microbiology.* 1998;144 (Pt 11): 3049–3060.
- 521 48. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of
522 methicillin-resistant and methicillin-susceptible clones of *Staphylococcus aureus*. *J Clin Microbiol.* 2000;38: 1008–
523 1015.
- 524 49. Furstenau TN, Cocking JH, Sahl JW, Fofanov VY. Variant site strain typer (VaST): efficient strain typing using a
525 minimal number of variant genomic sites. *BMC Bioinformatics.* 2018;19: 222.